Kolon Life Science’s osteoarthritis therapy ‘Invossa K’ landed in 60 general hospitals

Published: 2018-06-14 16:34:15

Updated: 2018-06-14 16:36:05

‘Invossa,’ a gene therapy for osteoarthritis, will start to be prescribed in general hospitals.

Kolon Life Science(CEO Woo-Seok Lee) and Mundipharma(CEO Myung-Sae Lee) announced on the 11^th that the world’s first and only ‘Invossa® K’ passed 60 major general hospitals’ drug committee as well as its first prescription in Seoul National University Hospital.

Invossa® K is being quickly landing i...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.